Abciximab


- TRADE NAME: ReoPro (Janssen Biotech)
- INDICATIONS: Thrombotic arterial disease
- SYNONYM: C7E3
- CLASS: Antiplatelet, Glycoprotein IIb/IIIa inhibitor, Monoclonal antibody
- HALF-LIFE: 10–30 minutes – given intravenously
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Anticoagulants, Antiplatelets, Collagenase, Dasatinib, Dextran, Drotrecogin Alfa, Fondaparinux, Glucosamine, Herbals with anticoagulant properties, Lepirudin, Monoclonal antibodies, NSAIDs, Omega-3 Fatty Acids, Pentosan, Pentoxifylline, Prostacyclin analogues, Reteplase, Salicylates, Thrombolytic agents, Tositumomab & Iodine131, Trastuzumab
PREGNANCY CATEGORY: C
Please login to see the rest of this drug profile
SKIN.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
LOCAL.
NEUROMUSCULAR/SKELETAL.
OTHER.
Page last updated 08/02/2021
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations 
- Breast feeding
- Geriatric
- Pediatric